Anesthetic

North America Anesthesia Drugs Market 2019-2024: Baxter International, Fresenius, Eisai, Roche, and B. Braun Melsungen Hold Substantial Market Shares - ResearchAndMarkets.com

Retrieved on: 
Friday, June 21, 2019
Health, Pharmaceutical, Medical specialties, Medicine, Regional anesthesia, Anesthesia, Anesthesiology, Local anesthesia, Anesthetic, Spinal anaesthesia, Nerve block, Local anesthetic

The "North America Anesthesia Drugs Market - Growth, Trends, and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Anesthesia Drugs Market - Growth, Trends, and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The North America Anesthesia Drugs Market is expected to register a CAGR of nearly 3.5% during the forecast period, 2019-2024.
  • There are several types of anesthetic drugs available in the market, such as general anesthesia, spinal anesthesia, IV regional anesthesia, local anesthesia, peripheral nerve block, and saddle block or caudal anesthesia.
  • Companies, like Baxter International, Fresenius SE & Co. KGaA, Eisai Co. Ltd, Roche Holding AG, and B. Braun Melsungen AG, hold substantial market shares in the anesthesia drugs market.

Gebauer's Pain Ease® Celebrates over 12 years with 12% more

Retrieved on: 
Wednesday, February 6, 2019
Drugs, Medical specialties, Psychoactive drugs, Anesthesia, Local anesthetics, General anesthetics, NMDA receptor antagonists, Sodium channel blockers, Topical anesthetic, Anesthetic, Pain, Ketamine

CLEVELAND, Feb. 6, 2019 /PRNewswire/ --Gebauer Company is celebrating more than 12 years since the launch of their bestselling non-flammable topical anesthetic product, Pain Ease, by adding 12% more product to every can.

Key Points: 
  • CLEVELAND, Feb. 6, 2019 /PRNewswire/ --Gebauer Company is celebrating more than 12 years since the launch of their bestselling non-flammable topical anesthetic product, Pain Ease, by adding 12% more product to every can.
  • "With over 12 successful years of making trips to the doctor easier and less painful, we are celebrating with 12% more product in every can of Pain Ease for the same price."
  • Pain Easeis a preferred instant topical anesthetic of healthcare professionals for pain in hospitals and medical specialties including emergency medicine, anesthesia, dermatology and pediatrics.
  • "This year Gebauer developed a new exclusive FDA-cleared cotton application method for Pain Ease, ideal for sensitive patients and children," said Sue Zagula, Clinical Marketing Manager.

Global Anesthesia Drugs Market by Drug Type, Route of Administration, Application and Geography - Forecast to 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 23, 2019
Health, Pharmaceutical, Medical specialties, Drugs, Medicine, Anesthesia, Regional anesthesia, Anesthesiology, Anesthetic, Surgery, Ketamine, Local anesthetic

The number of surgeries being performed is rising every year.

Key Points: 
  • The number of surgeries being performed is rising every year.
  • The overall increase in the number of surgeries performed has a strong impact on the anesthetics market, as anesthetic drugs are used in surgical procedures to reduce the pain during surgery.
  • Along with rising surgeries, other factors such as new anesthetic drugs and reduction in the cost of newly invented drugs are also driving the market.
  • Hence, the side-effects of general anesthesia and patient's reluctance towards using it, along with lack of skilled anesthetics and regulatory issues are restraining the market growth.

Development of Long-Acting Local Anesthetics

Retrieved on: 
Thursday, November 8, 2018
Neurochemistry, Medicine, Cell signaling, Anesthesia, Anesthetic, Pain management, Local anesthetic, RTT, Ketamine

"While it's not always possible to provide opioid-free pain control, judicious use of long-acting local anesthetics has already shown promise in reducing patient exposure to postoperative narcotics.

Key Points: 
  • "While it's not always possible to provide opioid-free pain control, judicious use of long-acting local anesthetics has already shown promise in reducing patient exposure to postoperative narcotics.
  • There is a significant need for even longer-acting local anesthetics; studies have shown that patients often have less pain overall, fewer side effects, and recover function more quickly when longer-acting local anesthetics are used as part of a comprehensive pain control strategy."
  • Dr. Singla also participated in a Panel Discussion with Nathaniel Katz, MD, MS, and Robert H. Dworkin, PhD.
  • Led by Dr. Neil Singla, Lotus focuses on optimizing design/conduct of clinical trials in pain providing scientific leadership at every step of the development process.

Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) Label Expansion

Retrieved on: 
Friday, June 1, 2018
Neurochemistry, Cell signaling, Chemistry, Dog health, Euphoriants, General anesthetics, RTT, Animal welfare, Onychectomy, Anesthetic, Ketamine

The filing is intended to expand the NOCITA label to include its use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy.

Key Points: 
  • The filing is intended to expand the NOCITA label to include its use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy.
  • NOCITA is a long-acting, local anesthetic that provides up to 72 hours of analgesia post-operatively using multi-vesicular liposomal technology.
  • The therapeutic was FDA-approved in August 2016 in dogs to provide local post-operative analgesic for cranial cruciate ligament surgery.
  • Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats.